Aspartyl-Alanyl-Diketopiperazine

Summary

Aspartyl-Alanyl-Diketopiperazine (CHEMBL4297349) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including osteoarthritis, knee and severe acute respiratory syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 6
• Chemistry: 186.17 Da · C7H10N2O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297349
Name	Aspartyl-Alanyl-Diketopiperazine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9815453
Molecular formula	C7H10N2O4
Molecular weight	186.17
InChIKey	RVLCUCVJZVRNDC-IMJSIDKUSA-N

SMILES: C[C@H]1C(=O)N[C@H](C(=O)N1)CC(=O)O

IUPAC name: 2-[(2S,5S)-5-methyl-3,6-dioxopiperazin-2-yl]acetic acid

Also known as: Ampion, Da-dkp, Dmi 9523, DMI-9523, DMI9523

Patent coverage: 96 distinct patent families (269 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
osteoarthritis, knee	3	MONDO:0005416	EFO:0004616
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE1	3
PHASE2	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03988023	PHASE3	TERMINATED	Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee.
NCT04839965	PHASE2	TERMINATED	Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen
NCT04868890	PHASE2	TERMINATED	A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19
NCT04456452	PHASE1	COMPLETED	Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation
NCT04606784	PHASE1	COMPLETED	Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress
NCT04880161	PHASE1	COMPLETED	A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).